or Try an Advanced Search...

    Her2 Stocks List

    Symbol Grade Name % Change
    MACK A Merrimack Pharmaceuticals, Inc. 0.00
    GTHX B G1 Therapeutics, Inc. 2.20
    ELVN B Enliven Therapeutics, Inc. -1.42
    MRKR B Marker Therapeutics, Inc. 5.61
    PBYI D Puma Biotechnology Inc -0.77
    GLSI D Greenwich LifeSciences, Inc. 3.55
    ZYME F Zymeworks Inc. -1.72
    OLMA F Olema Pharmaceuticals, Inc. 1.32
    ZNTL F Zentalis Pharmaceuticals, Inc. -3.31
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Cancer Her2/Neu Breast Cancer Treatment Of Breast Cancer Medicine Epidermal Growth Factor Receptor Tyrosine Kinase Receptors Antiestrogens Estrogen Estrogen Receptor Hormones Protein Kinase Inhibitor Selective Estrogen Receptor Degraders Treatment Of Cancer Cancer Immunotherapy Cancer Treatment Clinical Medicine Drugs Fulvestrant

    Related ETFs - A few ETFs which own one or more of the above listed Her2 stocks.

    Symbol Grade Name Weight
    CNCR D Loncar Cancer Immunotherapy ETF 3.55
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 1.41
    LABD B Direxion Daily S&P Biotech Bear 3X Shares 1.07
    SBIO D ALPS Medical Breakthroughs ETF 1.01
    XBI D SPDR S&P Biotech ETF 0.86
    View all Her2 ETFs...
    Compare ETFs
    Compare BBC to SBIO Compare CNCR to SBIO Compare LABD to SBIO

        Her2 Stocks Recent News

        Date Stock Title
        Apr 19 ELVN MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
        Apr 19 GTHX G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit
        Apr 18 ELVN Enliven Therapeutics files to sell 6.43M shares for holders
        Apr 18 PBYI Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
        Apr 18 ZYME Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
        Apr 17 GTHX G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Cancer Her2/Neu Breast Cancer Treatment Of Breast Cancer Medicine Epidermal Growth Factor Receptor Tyrosine Kinase Receptors Antiestrogens Estrogen Estrogen Receptor Hormones Protein Kinase Inhibitor Selective Estrogen Receptor Degraders Treatment Of Cancer Cancer Immunotherapy Cancer Treatment Clinical Medicine Drugs Fulvestrant
        Her2

        Receptor tyrosine-protein kinase erbB-2, also known as CD340 (cluster of differentiation 340), proto-oncogene Neu, Erbb2 (rodent), or ERBB2 (human), is a protein that in humans is encoded by the ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B, a gene isolated from avian genome. It is also frequently called HER2 (from human epidermal growth factor receptor 2) or HER2/neu.HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients.

        More about Her2
        Browse All Tags